Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

The United States has led the world in pharmaceutical innovation for decades by developing drugs that combat cancer, heart ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

For decades, the United States has led the world in pharmaceutical innovation – developing drugs that combat cancer, heart ...

New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it.

This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...